- Conditions
- X-Linked Myotubular Myopathy
- Interventions
- ASP2957, Methylprednisolone, Prednisolone, Sirolimus
- Genetic · Drug
- Lead sponsor
- Astellas Gene Therapies
- Industry
- Eligibility
- Up to 36 Months · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Portland, Oregon + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Males With X-linked Myotubular Myopathy (XLMTM)
- Interventions
- Non-interventional, retrospective medical chart review
- Other
- Lead sponsor
- Astellas Gene Therapies
- Industry
- Eligibility
- Male only
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 6
- States / cities
- San Pedro, California • Aurora, Colorado • Gainesville, Florida + 3 more
- Conditions
- Pompe Disease (Late-onset)
- Interventions
- No Intervention
- Other
- Lead sponsor
- Astellas Gene Therapies
- Industry
- Eligibility
- 16 Years to 69 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 10
- States / cities
- Atlanta, Georgia • Kansas City, Kansas • Ann Arbor, Michigan + 7 more
- Conditions
- X-Linked Myotubular Myopathy
- Interventions
- Resamirigene bilparvovec
- Genetic
- Lead sponsor
- Astellas Gene Therapies
- Industry
- Eligibility
- Up to 5 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2030
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Chicago, Illinois • Bethesda, Maryland
- Conditions
- X-Linked Myotubular Myopathy
- Interventions
- No Intervention
- Other
- Lead sponsor
- Astellas Gene Therapies
- Industry
- Eligibility
- Up to 17 Years · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Santa Monica, California • Chicago, Illinois • Boston, Massachusetts + 4 more
- Conditions
- X-linked Myotubular Myopathy
- Interventions
- Not listed
- Lead sponsor
- Astellas Gene Therapies
- Industry
- Eligibility
- Up to 3 Years · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Gainesville, Florida • Chicago, Illinois + 1 more
- Conditions
- Pompe Disease (Late-onset)
- Interventions
- zocaglusagene nuzaparvovec
- Genetic
- Lead sponsor
- Astellas Gene Therapies
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2035
- U.S. locations
- 3
- States / cities
- Orange, California • Palo Alto, California • Salt Lake City, Utah